In vitro potency of amikacin against carbapenem-resistant Pseudomonas aeruginosa: A target for nebulization strategy?

Braz J Infect Dis. 2022 Mar-Apr;26(2):102355. doi: 10.1016/j.bjid.2022.102355. Epub 2022 Apr 28.

Authors

Gabriel T Cuba¹, Paulo H D Santos², Antonio C C Pignatari², David P Nicolau³, Carlos R V Kiffer²

Affiliations

¹ Universidade Federal de São Paulo (UNIFESP), Escola Paulista de Medicina, São Paulo, SP, Brazil; Universidade de São Paulo (HCFMUSP), Hospital das Clínicas, Faculdade de Medicina, São Paulo, SP, Brazil. Electronic address: gbtrova@gmail.com.
² Universidade Federal de São Paulo (UNIFESP), Escola Paulista de Medicina, São Paulo, SP, Brazil.
³ Center of Anti-infective Research and Development, Hartford Hospital, Hartford, CT, United States.

No abstract available

MeSH terms

Amikacin* / pharmacology
Anti-Bacterial Agents / pharmacology
Carbapenems / pharmacology
Humans
Microbial Sensitivity Tests
Pseudomonas Infections* / drug therapy
Pseudomonas aeruginosa

Substances

Anti-Bacterial Agents
Carbapenems
Amikacin